![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Glenmark to Begin Phase 3 Trial of Favipiravir and Umifenovir for COVID-19
Glenmark to Begin Phase 3 Trial of Favipiravir and Umifenovir for COVID-19
![](https://www.fdanews.com/ext/resources/test/Drug-Images4/GlenmarkPharma_Logo.gif?t=1562713329&width=430)
Glenmark will conduct a phase 3 trial in India, testing the efficacy of antivirals favipiravir and umifenovir for the treatment of COVID-19.
The trial will examine if early administration of the drug combination will enhance efficacy in 158 hospitalized patients with moderate COVID-19, who will be randomized to receive either favipiravir with or without umifenovir along with the standard of care.
The company is also conducting phase 3 trials of favipiravir as a COVID-19 monotherapy in 150 patients from nine hospitals across India.
Upcoming Events
-
21Oct